One of the greatest medical breakthroughs of our time is the proven evidence of the eradication of the Herpes Simplex Virus achieved by Synergy. From our findings, this is the first of its kind, bringing us one step closer to ending HSV worldwide.
In terms of the research conducted to date, Synergy conducted clinical trials with longitudinal studies of infected patients. The test involved measuring patients’ responses to the five core compounds (5CC) product at various stages of the trial.
The patients were randomly chosen for the trial, and the study group consisted of patients infected with the disease for varying lengths of time. Researchers at Synergy administered an IgG herpes antibody serology blood test analysis, instead of an IgM test analysis.
IgM and IgG are both classes of immunoglobulin (antibodies). While the IgM is produced immediately upon the pathogen’s entry into the body, the IgG is produced after a period of delay. The choice of IgG analysis over IgM analysis was predominantly because of the differences in infection time between patients.
The first set of tests involved administering single ingredients to patients. This proved to be ineffective in treating Herpes. The second set of tests involved administering a combination of ingredients to patients. This latter approach proved exceptionally successful. Over 70% of the positive-diagnosed patients were completely herpes-free in a matter of months. Further tests revealed the ideal treatment time frame to be the 6 month window.
Synergy also conducted tests on treated patients to check for signs of recurrence. Test results proved that once destroyed, the Herpes virus was no longer present in the bloodstream and there was no recurrence in any patient. Additional tests validated the complete elimination of viral cells post-treatment.
The remaining portion of the study group, who still had high levels of IgG markers, continued to be tested. Although still infected, tests proved a steady decline in infection rate and herpes antibody activity, over an extended period of time. Recurrence of outbreaks also became less frequent, and the patients were noted to experience an overall sense of well being. In both sets of patients, the immune system was noted to have become stronger post-treatment.
“In this analysis, targeting different phases of the herpes virus cycle, including entry stage, reproductive cross mutation, cell-to-cell infection, can represent a systemic vantage point for obtaining the structural understanding on cell inhibition and breakdown. Under these perspectives, testing consisted of 5 core compounds (5CC) immunotherapeutic, capable of neutralizing human monoclonal antibodies. In the study, tested for the first time 5CC combinations of inhibitors of Herpes virus DNA synthesis and interferon (IFN)-induced cellular antiviral response neutralized against viral reproduction by blocking cell to cell infection…. Virus HSV-1 and HSV-2 titers were reduced significantly with 5CC to the point of negative ranges 0.01 – 0.09 in 72%… This represents a focus away from standardised antiherpetic medications in favour of the naturally occurring compounds derived from the combination. To our knowledge, no placebo controlled, double-blind studies have been done with other natural remedies or standardized antiherpetic medication against herpes with the same degree of efficacy.”
Post treatment due to there no longer being any antibodies to the virus, it is important to note that the participants did not have any level of immunity towards the Herpes virus. Therefore if a person post treatment is exposed to the Herpes virus once again, it would be possible to contract the virus once again. There was no re occurrence of the virus or antibody levels except in the case of reinfection.
Synergy’s Herpes treatment formulation has been extremely successful in treating genital and oral HSV. Now researchers hope to extend the scope of treatment to treat other viral conditions like Human Immunodeficiency Virus (HIV) and the Epstein Barr Virus (EBV). Studies are underway to understand how best this formulation can be applied to other diseases. If you are interested in future studies in HIV in particular please email the staff at firstname.lastname@example.org
Participants, Pathology centers’ and Doctors names and details have been kept anonymous to protect their privacy. The results indicated here include some test outcomes with a Borderline status to demonstrate that for some people the transition may not be from a Positive to Negative result. The terminology of an Equivocal or Borderline result in some of these tests refers to a bare trace of the viral antibodies still being present. In this instance, the person would no longer be suffering from viral related outbreaks as the viral cells have been eliminated and the antibody levels are diminishing greatly to the point of being barely traceable.